A federal jury in Delaware has awarded Regeneron (NASDAQ:REGN) more than $400M in damages after finding that Amgen ...

A federal jury in Delaware said on Thursday that biotech company Amgen owes competitor Regeneron more than $406 million for ...

In the long-running feud between Regeneron and Amgen around the companies’ competing PCSK9 cholesterol meds, Regeneron has ...

White & Case secures $405M jury win for Regeneron in antitrust case, with Amgen found liable for anti-competitive bundling ...

Regeneron Pharmaceuticals won $406.8 million in damages for a lawsuit claiming Amgen violated antitrust and tort laws. A jury in a Delaware court found that Amgen violated certain laws, and gave ...

Inebilizumab was especially effective for patients with pancreatic and biliary immunoglobulin G4-related disease, with ...

Shares of Amgen (AMGN) have been trending lower with the Health Care sector. But the sell off may soon come to an end.

Shares of Amgen Inc. AMGN slipped 1.37% to $272.05 Thursday, on what proved to be an all-around positive trading session for ...

Regeneron's lead counsel was Jonathan D. Polkes of White & Case LLP.

Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options ...

Some research has shown that dividend-paying stocks significantly outperformed their non-dividend-paying peers over the past ...

Readers hoping to buy Amgen Inc. (NASDAQ:AMGN) for its dividend will need to make their move shortly, as the stock is about to trade ex-dividend. The ex-dividend date is usually set to be one ...